A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Recruiting now

Conditions studied: Non-small Cell Lung Cancer Stage IIIA

In brief

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Key facts

Study ID

NCT05732974

Run by

University Hospital, Toulouse

People needed

60

Starts

2023-03-30

Expected to finish

2026-10-30

Last updated by the study team

2023-09-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with an early stage of non small cell lung cancer
• Indication of surgical resection
• Patient able to understand and give his consent
• Patient affiliated to the health insurance

You may not qualify if…

• Patient with another cancer in the last 5 years
• Patient with an allergy to the contrast medium
• Patient under legal protection

Where it is running

• Julien MAZIERES — Toulouse, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.